Search

Your search keyword '"Loiacono, Ferdinando"' showing total 48 results
Start Over Author "Loiacono, Ferdinando"
48 results on '"Loiacono, Ferdinando"'

1. The long Pentraxin PTX3 serves as an early predictive biomarker of co-infections in COVID-19

Author

Accornero, Stefano, Aghemo, Alessio, Ali, Hussam, Angelini, Claudio, Arcari, Ivan, Arosio, Paola, Azzolini, Elena, Baccarin, Alessandra, Badalamenti, Salvatore, Baggio, Sara, Barbagallo, Michela, Barberi, Caterina, Barbic, Franca, Barbieri, Viviana, Barbone, Alessandro, Basciu, Alessio, Bocciolone, Monica, Borea, Federica, Borroni, Mario, Bresciani, Gianluigi, Brunetta, Enrico, Bulletti, Cinzia, Cadonati, Cristina, Calabro', Lorenzo, Calatroni, Marta, Calvetta Albania, Antonietta, Cannata, Francesco, Canziani, Lorenzo, Capretti Giovanni, Luigi, Carlani, Elisa, Carrone, Flaminia, Casana, Maddalena, Cecconi, Maurizio, Ceriotti, Carlo, Ciccarelli, Michele, Cimino, Matteo, Ciuffini, Leonardo, Colaizzi, Chiara, Colapietro, Francesca, Costa, Guido, Cozzi, Ottavia, Craviotto, Vincenzo, Crespi, Chiara, Crippa, Massimo, Da Rio, Leonardo, Dal Farra, Sara, D'Antonio, Federica, De Ambroggi, Guido, De Donato, Massimo, De Lucia, Francesca, De Santis, Maria, Delle Rose, Giacomo, Di Pilla, Marina, Dipaola, Franca, Dipasquale, Andrea, Dipasquale, Angelo, Droandi, Ginevra, Fazio, Roberta, Ferrante, Giuseppe, Ferrara Elisa, Chiara, Ferrari Matteo, Carlo, Ferri, Sebastian, Folci, Marco, Foresti, Sara, Franchi, Eloisa, Fraolini, Elia, Fugazza, Alessandro, Furfaro, Federica, Galimberti, Paola, Galtieri Alessia, Piera, Gavazzi, Francesca, Generali, Elena, Goletti, Benedetta, Guidelli, Giacomo, Jacobs, Flavia, Kurihara, Hayato, Lagioia, Michele, Libre', Luca, Lleo, Ana, Loiacono, Ferdinando, Lughezzani, Giovanni, Maccallini, Marta, Maiorino Alfonso, Francesco, Malesci, Alberto, Mantovani, Riccardo, Marchettini, Davide, Marinello, Arianna, Markopoulos, Nikolaos, Masetti, Chiara, Milani, Angelo, Mirani, Marco, Morelli, Paola, Motta, Francesca, Mundula, Valeria, Nigro, Mattia, Omodei, Paolo, Ormas, Monica, Pagliaro, Arianna, Paliotti, Roberta, Parigi Tommaso, Lorenzo, Pedale, Rosa, Pegoraro, Francesco, Pellegatta, Gaia, Pellegrino, Marta, Petriello, Gennaro, Piccini, Sara, Pocaterra, Daria, Poliani, Laura, Preatoni, Paoletta, Procopio, Fabio, Puggioni, Francesca, Pugliese, Luca, Racca, Francesca, Randazzo, Michele, Regazzoli Lancini, Damiano, Reggiani, Francesco, Rodolfi, Stefano, Ruongo, Lidia, Sacco, Clara, Sandri Maria, Teresa, Savi, Marzia, Scarfo', Iside, Shiffer, Dana, Sicoli, Federico, Solano, Simone, Solitano, Virginia, Stainer, Anna, Stella Matteo, Carlo, Strangio, Giuseppe, Taormina, Antonio, Testoni, Lucia, Tordato, Federica, Trabucco, Angela, Ulian, Luisa, Valentino, Rossella, Valeriano, Chiara, Vena, Walter, Verlingieri, Simona, Vespa, Edoardo, Voza, Antonio, Zanuso, Valentina, Zilli, Alessandra, Anfray, Clement, Belgiovine, Cristina, Bertocchi, Alice, Bombace, Sara, Brescia, Paola, Calcaterra, Francesca, Calvi, Michela, Cancellara, Assunta, Capucetti, Arianna, Carenza, Claudia, Carloni, Sara, Carnevale, Silvia, Cazzetta, Valentina, Coianiz, Nicolò, Darwich, Abbass, Davoudian, Sadaf, De Paoli, Federica, Di Donato, Rachele, Digifico, Elisabeth, Durante, Barbara, Farina Floriana, Maria, Ferrari, Valentina, Fornasa, Giulia, Franzese, Sara, Ghasemi, Somayehsadat, Gil Gomez, Antonio, Giugliano, Silvia, Gomes Ana, Rita, Lizier, Michela, Lo Cascio, Antonino, Melacarne, Alessia, Mozzarelli, Alessandro, My, Ilaria, Oresta, Bianca, Pasqualini, Fabio, Pastò, Anna, Pelamatti, Erica, Perucchini, Chiara, Pozzi, Chiara, Rimoldi, Valeria, Rimoldi, Monica, Scarpa, Alice, Scavello, Francesco, Silvestri, Alessandra, Sironi, Marina, Spadoni, Ilaria, Spano', Salvatore, Spata, Gianmarco, Supino, Domenico, Tentorio, Paolo, Ummarino, Aldo, Valentino, Sonia, Zaghi, Elisa, Zanon, Veronica, Mapelli, Sarah N., Nappi, Emanuele, García Martín, Ian David, Leone, Roberto, Angelotti, Giovanni, Zhong, Hang, Magrini, Elena, Stravalaci, Matteo, Protti, Alessandro, Santini, Alessandro, Costantini, Elena, Savevski, Victor, Bottazzi, Barbara, Bartoletti, Michele, Mantovani, Alberto, and Garlanda, Cecilia

Published
2024
Full Text
View/download PDF

2. Clinical burden and predictors of non-cardiovascular mortality and morbidity in advanced heart failure

Author

Stolfo, Davide, Pagnesi, Matteo, Chiarito, Mauro, Baldetti, Luca, Merlo, Marco, Lombardi, Carlo M., Loiacono, Ferdinando, Gregorio, Caterina, Cappelletti, Alberto M., Contessi, Stefano, Cocianni, Daniele, Perotto, Maria, Adamo, Marianna, Calì, Filippo, Inciardi, Riccardo M., Tomasoni, Daniela, Maccallini, Marta, Villaschi, Alessandro, Gasparini, Gaia, Montella, Marco, Barone, Giuseppe, Pini, Daniela, Metra, Marco, and Sinagra, Gianfranco

Published
2024
Full Text
View/download PDF

4. Characteristics and outcomes of patients with tricuspid regurgitation and advanced heart failure

Author

Pagnesi, Matteo, Riccardi, Mauro, Chiarito, Mauro, Stolfo, Davide, Baldetti, Luca, Lombardi, Carlo Mario, Colombo, Giada, Inciardi, Riccardo Maria, Tomasoni, Daniela, Loiacono, Ferdinando, Maccallini, Marta, Villaschi, Alessandro, Gasparini, Gaia, Montella, Marco, Contessi, Stefano, Cocianni, Daniele, Perotto, Maria, Barone, Giuseppe, Merlo, Marco, Cappelletti, Alberto Maria, Sinagra, Gianfranco, Pini, Daniela, Metra, Marco, and Adamo, Marianna

Published
2024
Full Text
View/download PDF

5. Clinical and prognostic implications of heart failure hospitalization in patients with advanced heart failure

Author

Pagnesi, Matteo, Sammartino, Antonio Maria, Chiarito, Mauro, Stolfo, Davide, Baldetti, Luca, Adamo, Marianna, Maggi, Giuseppe, Inciardi, Riccardo Maria, Tomasoni, Daniela, Loiacono, Ferdinando, Maccallini, Marta, Villaschi, Alessandro, Gasparini, Gaia, Montella, Marco, Contessi, Stefano, Cocianni, Daniele, Perotto, Maria, Barone, Giuseppe, Merlo, Marco, Cappelletti, Alberto Maria, Sinagra, Gianfranco, Pini, Daniela, Metra, Marco, and Lombardi, Carlo Mario

Published
2024
Full Text
View/download PDF

6. Ischemic Etiology in Advanced Heart Failure: Insight from the HELP-HF Registry

Author

Villaschi, Alessandro, Pagnesi, Matteo, Stolfo, Davide, Baldetti, Luca, Lombardi, Carlo Mario, Adamo, Marianna, Loiacono, Ferdinando, Sammartino, Antonio Maria, Colombo, Giada, Tomasoni, Daniela, Inciardi, Riccardo Maria, Maccallini, Marta, Gasparini, Gaia, Montella, Marco, Contessi, Stefano, Cocianni, Daniele, Perotto, Maria, Barone, Giuseppe, Merlo, Marco, Cappelletti, Alberto Maria, Sinagra, Gianfranco, Pini, Daniela, Metra, Marco, and Chiarito, Mauro

Published
2023
Full Text
View/download PDF

7. Detailed Assessment of the “I Need Help” Criteria in Patients With Heart Failure: Insights From the HELP-HF Registry

Author

Pagnesi, Matteo, Ghiraldin, Daniele, Vizzardi, Enrico, Chiarito, Mauro, Stolfo, Davide, Baldetti, Luca, Adamo, Marianna, Lombardi, Carlo Mario, Inciardi, Riccardo Maria, Tomasoni, Daniela, Loiacono, Ferdinando, Maccallini, Marta, Villaschi, Alessandro, Gasparini, Gaia, Montella, Marco, Contessi, Stefano, Cocianni, Daniele, Perotto, Maria, Barone, Giuseppe, Sartori, Samantha, Davison, Beth A., Merlo, Marco, Cappelletti, Alberto Maria, Sinagra, Gianfranco, Pini, Daniela, and Metra, Marco

Published
2023
Full Text
View/download PDF

8. Impact of malnutrition in patients with severe heart failure

Author

Pagnesi, Matteo, primary, Serafini, Lisa, additional, Chiarito, Mauro, additional, Stolfo, Davide, additional, Baldetti, Luca, additional, Inciardi, Riccardo M., additional, Tomasoni, Daniela, additional, Adamo, Marianna, additional, Lombardi, Carlo M., additional, Sammartino, Antonio M., additional, Loiacono, Ferdinando, additional, Maccallini, Marta, additional, Villaschi, Alessandro, additional, Gasparini, Gaia, additional, Montella, Marco, additional, Contessi, Stefano, additional, Cocianni, Daniele, additional, Perotto, Maria, additional, Barone, Giuseppe, additional, Anker, Stefan D., additional, Merlo, Marco, additional, Cappelletti, Alberto M., additional, Sinagra, Gianfranco, additional, Pini, Daniela, additional, and Metra, Marco, additional

Published
2024
Full Text
View/download PDF

9. Frailty according to the 2019 HFA‐ESC definition in patients at risk for advanced heart failure: Insights from the HELP‐HF registry

Author

Villaschi, Alessandro, primary, Chiarito, Mauro, additional, Pagnesi, Matteo, additional, Stolfo, Davide, additional, Baldetti, Luca, additional, Lombardi, Carlo Mario, additional, Adamo, Marianna, additional, Loiacono, Ferdinando, additional, Sammartino, Antonio Maria, additional, Colombo, Giada, additional, Tomasoni, Daniela, additional, Inciardi, Riccardo Maria, additional, Maccallini, Marta, additional, Gasparini, Gaia, additional, Montella, Marco, additional, Contessi, Stefano, additional, Cocianni, Daniele, additional, Perotto, Maria, additional, Barone, Giuseppe, additional, Merlo, Marco, additional, Vitale, Cristiana, additional, Rosano, Giuseppe Massimo Claudio, additional, Cappelletti, Alberto Maria, additional, Sinagra, Gianfranco, additional, Metra, Marco, additional, and Pini, Daniela, additional

Published
2024
Full Text
View/download PDF

10. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Bazzalo, Ignacio J., Casas, Marcelo M., Nuñez, Sebastián A., Pere, Yael, Ibarrola, Carlos M., Solis Aramayo, Marco A., Cuesta, Maria C., Duarte, Andrea E., Gutierrez Fernandez, Pablo M., Iannantuono, Maria A., Miyazaki, Erica A., Silvio, Javier P., Scublinsky, Dario G., Bales, Alessandra, Catarino, Daniela, Fiss, Elie, Mohrbacher, Sara, Sato, Victor, Baylao, Antonio, Cavalcante, Adilson, Correa, Francini, de Andrade, Celso A., Furtado, Juvencio, Ribeiro Filho, Nelson, Telles, Valéria, Trevelin, Leopoldo T., Vipich, Ricardo, Boldo, Rodrigo, Borges, Paula, Lobo, Suzana, Luckemeyer, Graziela, Machado, Luana, Alves, Maysa B., Iglessias, Ana C., Lago, Marianna M., Santos, Daniel W., Chapdelaine, Hugo, Falcone, Emilia L., Jamal, Rahima, Luong, Me-Linh, Durand, Madeleine, Doucet, Stephane, Carrier, François-Martin, Coburn, Bryan A., Del Sorbo, Lorenzo, Walmsley, Sharon L., Belga, Sara, Chen, Luke Y., Mah, Allison D., Steiner, Theodore, Wright, Alissa J., Hajek, J., Adhikari, Neill, Fowler, Robert A., Daneman, Nick, Khwaja, Kosar A., Shahin, Jason, Gonzalez, Carolina, Silva, Rafael, Lindh, Marcelo, Maluenda, Gabriel, Fernandez, Patricia, Oyonarte, Maite, Lasso, Martin, Boyer, Alexandre, Bronnimann, Didier, Bui, Hoang-Nam, Cazanave, Charles, Chaussade, Helene, Desclaux, Arnaud, Ducours, Mailys, Duvignaud, Alexandre, Malvy, Denis, Martin, Lisa, Neau, Didier, Nguyen, Duc, Pistone, Thierry, Soubrane-Wirth, Gaetane, Leitao, Julie, Allavena, Clotilde, Biron, Charlotte, Bouchez, Sabelline, Gaborit, Benjamin, Gregoire, Antoine, Le Turnier, Paul, Lecompte, Anne-Sophie, Lecomte, Raphael, Lefebvre, Maeva, Raffi, Francois, Boutoille, David, Morineau, Pascale H., Guéry, Romain, Chatelus, Emmanuel, Dumoussaud, Nathalie, Felten, Renaud, Luca, Florina, Goichot, Bernard, Schneider, Francis, Taquet, Marie-Caroline, Groh, Matthieu, Roumier, Mathilde, Neuville, Mathilde, Bachelard, Antoine, Isernia, Valentina, Lescure, F-Xavier, Phung, Bao-Chau, Rachline, Anne, Sautereau, Aurelie, Vallois, Dorothee, Bleher, Yves, Boucher, Delphine, Coudon, Clémentine, Esnault, Jean, Guimard, Thomas, Leautez-Nainville, Sophie, Merrien, Dominique, Morrier, Marine, Motte-Vincent, Pauline, Gabeff, Romain, Leclerc, Hélène, Cozic, Céline, Decours, Romain, Février, Ronan, Colin, Gwenhael, Abgrall, Sophie, Vignes, Dorothee, Sterpu, Raluca, Kuellmar, Mira, Meersch-Dini, Melanie, Weiss, Raphael, Zarbock, Alexander, Antony, Christiane, Berger, Marc, Brenner, Thorsten, Taube, Christian, Herbstreit, Frank, Dolff, Sebastian, Konik, Margarethe, Schmidt, Karsten, Zettler, Markus, Witzke, Oliver, Boell, Boris, Garcia Borrega, Jorge, Koehler, Philipp, Zander, Thomas, Dusse, Fabian, Al-Sawaf, Othman, Köhler, Philipp, Eichenauer, Dennis, Kochanek, Matthias, Shimabukuro-Vornhagen, Alexander, Mellinghoff, Sibylle, Claßen, Annika, Heger, Jan-Michel, Meyer-Schwickerath, Charlotte, Liedgens, Paul, Heindel, Katrin, Belkin, Ana, Biber, Asaf, Gilboa, Mayan, Levy, Itzchak, Litachevsky, Vladislav, Rahav, Galia, Finesod Wiedner, Anat, Zilberman-Daniels, Tal, Oster, Yonatan, Strahilevitz, Jacob, Sviri, Sigal, Baldissera, Elena M., Campochiaro, Corrado, Cavalli, Giulio, Dagna, Lorenzo, De Luca, Giacomo, Della Torre, Emanuel, Tomelleri, Alessandro, Bernasconi De Luca, Davide, Capetti, Amedeo F., Coen, Massimo, Cossu, Maria V., Galli, Massimo, Giacomelli, Andrea, Gubertini, Guido A., Rusconi, Stefano, Burastero, Giulia J., Digaetano, Margherita, Guaraldi, Giovanni, Meschiari, Marianna, Mussini, Cristina, Puzzolante, Cinzia, Volpi, Sara, Aiello, Marina, Ariani, Alarico, Chetta, Alfredo A., Frizzelli, Annalisa, Ticinesi, Andrea, Tuttolomondo, Domenico, Aliberti, Stefano, Blasi, Francesco B., Di Pasquale, Marta F., Misuraca, Sofia, Pilocane, Tommaso, Simonetta, Edoardo, Aghelmo, Alessio M., Angelini, Claudio, Brunetta, Enrico, Canonica, Giorgio W., Ciccarelli, Michele, Dal Farra, Sara, De Santis, Maria, Ferri, Sebastian, Folci, Marco, Guidelli, Giacomo M., Heffler, Enrico M., Loiacono, Ferdinando, Malipiero, Giacomo, Paoletti, Giovanni, Pedale, Rosa, Puggioni, Francesca A., Racca, Francesca, Zumbo, Aurora, Satou, Morihiko, Honda, Hitoshi, Lisun, Tatyana, Protsenko, Denis, Rubtsov, Nikolay, Beloglazova, Irina, Fomina, Daria, Lysenko, Mariana, Serdotetskova, Sofia, Firstov, Vitali, Gordeev, Ivan, Kokorin, Ilia, Komissarova, Ksenia, Lapochkina, Nina, Luchinkina, Elena, Malimon, Valentin, Mamedguseyinova, Sevinch, Polubatonova, Ksenia, Suvorova, Natalia, Arribas, Jose, Borobia Perez, Alberto M., de la Calle Prieto, Fernando, Figueira, Juan Carlos, Motejano Sanchez, Rocio, Mora-Rillo, Marta, Prados Sanchez, Concepcion, Queiruga Parada, Javier, Fernandez Arnalich, Francisco, Guerro Barrientos, Maria, Bendala Estrada, Alejandro, Caballero Marcos, Aranzazu, Garcia Leoni, Maria E., García-Martínez, Rita, Collado, Ana María, Munoz Garcia, Patricia, Torres do Rego, Ana, Villalba García, María V., Burrillo, Almudena, Valerio Minero, Maricela, Gijon Vidaurreta, Paloma, Infante Herrero, Sonsoles, Velilla, Elena, Machado, Marina, Olmedo, Maria, Pinilla, Blanca, Almirante Gragera, Benito, Cañas Ruano, Maria de la Esperanza, Contreras Medina, Sofia, Cortés Herrera, Alejandro, Falcó Ferrer, Vicenç, Ferrer Roca, Ricard, Nuvials Casals, Xavier, Ribera Pascuet, Esteve, Suanzes Diez, Paula, Rebollo Castro, Pedro, Garcia Alcaide, Felipe, Soriano, Alejandro, Oliver Caldes, Aina, González Cordón, Ana, Cardozo, Celia, De la Mora Cañizo, Lorena, Pena López, Romina, Chamorro, Sandra, Crespillo-Andujar, Clara, Escudero Sanchez, Rosa, Fortún-Abete, Jesús, Monge-Maillo, Begoña, Moreno Zamora, Ana, Norman, Francesca, Sanchez Conde, Matilde, Serrano Villar, Sergio, Vizcarra, Pilar, Lescure, François-Xavier, Fowler, Robert A, Lazar, Jennifer Sloane, Shi, Genming, Wung, Peter, Patel, Naimish, and Hagino, Owen

Published
2021
Full Text
View/download PDF

11. Clinical and prognostic implications of heart failure hospitalization in patients with advanced heart failure

Author

Pagnesi, Matteo, primary, Sammartino, Antonio Maria, additional, Chiarito, Mauro, additional, Stolfo, Davide, additional, Baldetti, Luca, additional, Adamo, Marianna, additional, Maggi, Giuseppe, additional, Inciardi, Riccardo Maria, additional, Tomasoni, Daniela, additional, Loiacono, Ferdinando, additional, Maccallini, Marta, additional, Villaschi, Alessandro, additional, Gasparini, Gaia, additional, Montella, Marco, additional, Contessi, Stefano, additional, Cocianni, Daniele, additional, Perotto, Maria, additional, Barone, Giuseppe, additional, Merlo, Marco, additional, Cappelletti, Alberto Maria, additional, Sinagra, Gianfranco, additional, Pini, Daniela, additional, Metra, Marco, additional, and Lombardi, Carlo Mario, additional

Published
2023
Full Text
View/download PDF

12. Left Ventricular Fibrosis as a Main Determinant of Filling Pressures and Left Atrial Function in Advanced Heart Failure

Author

Mandoli, Giulia Elena, primary, Cameli, Matteo, additional, Pastore, Maria Concetta, additional, Loiacono, Ferdinando, additional, Righini, Francesca Maria, additional, D’Ascenzi, Flavio, additional, Focardi, Marta, additional, Cavigli, Luna, additional, Lisi, Matteo, additional, Bisleri, Gianluigi, additional, Dokollari, Aleksander, additional, Bernazzali, Sonia, additional, Maccherini, Massimo, additional, Valente, Serafina, additional, and Henein, Michael, additional

Published
2023
Full Text
View/download PDF

13. Left ventricular fibrosis as a main determinant of filling pressures and left atrial function in advanced heart failure.

Author

Mandoli, Giulia Elena, Cameli, Matteo, Pastore, Maria Concetta, Loiacono, Ferdinando, Righini, Francesca Maria, D'Ascenzi, Flavio, Focardi, Marta, Cavigli, Luna, Lisi, Matteo, Bisleri, Gianluigi, Dokollari, Aleksander, Bernazzali, Sonia, Maccherini, Massimo, Valente, Serafina, and Henein, Michael Y

Subjects
HEART disease diagnosis, HEART failure risk factors, RISK assessment, BIOPSY, HEART atrium, VENTRICULAR ejection fraction, PULMONARY artery, DESCRIPTIVE statistics, FIBROSIS, CARDIAC output, ELECTROCARDIOGRAPHY, HEART transplantation, COMPARATIVE studies, BLOOD pressure, CONFIDENCE intervals, PATIENT satisfaction, LEFT ventricular dysfunction, HEART ventricles, BIOMARKERS, CARDIAC catheterization, DISEASE complications
Abstract

Aims Advanced heart failure (AdHF) is characterized by variable degrees of left ventricular (LV) dysfunction, myocardial fibrosis, and raised filling pressures which lead to left atrial (LA) dilatation and cavity dysfunction. This study investigated the relationship between LA peak atrial longitudinal strain (PALS), assessed by speckle-tracking echocardiography (STE), and invasive measures of LV filling pressures and fibrosis in a group of AdHF patients undergoing heart transplantation (HTX). Methods and results We consecutively enrolled patients with AdHF who underwent HTX at our Department. Demographic and basic echocardiographic data were registered, then invasive intracardiac pressures were obtained from right heart catheterization, and STE was also performed. After HTX, biopsy specimens from explanted hearts were collected to quantify the degree of LV myocardial fibrosis. Sixty-four patients were included in the study (mean age 62.5 ± 11 years, 42% female). The mean LV ejection fraction (LVEF) was 26.7 ± 6.1%, global PALS was 9.65 ± 4.5%, and mean pulmonary capillary wedge pressure (PCWP) was 18.8 ± 4.8 mmHg. Seventy-three % of patients proved to have severe LV fibrosis. Global PALS was inversely correlated with PCWP (R = −0.83; P < 0.0001) and with LV fibrosis severity (R = −0.78; P < 0.0001) but did not correlate with LVEF (R = 0.15; P = 0.2). Among echocardiographic indices of LV filling pressures, global PALS proved the strongest [area under the curve 0.955 (95% confidence interval 0.87–0.99)] predictor of raised (>18 mmHg) PCWP. Conclusion In patients with AdHF, reduced global PALS strongly correlated with the invasively assessed LV filling pressure and degree of LV fibrosis. Such relationship could be used as non-invasive indicator for optimum patient stratification for therapeutic strategies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Guideline‐directed medical therapy in severe heart failure with reduced ejection fraction: an analysis from the HELP‐HF registry

Author

Tomasoni, Daniela, primary, Pagnesi, Matteo, additional, Colombo, Giada, additional, Chiarito, Mauro, additional, Stolfo, Davide, additional, Baldetti, Luca, additional, Lombardi, Carlo Mario, additional, Adamo, Marianna, additional, Maggi, Giuseppe, additional, Inciardi, Riccardo Maria, additional, Loiacono, Ferdinando, additional, Maccallini, Marta, additional, Villaschi, Alessandro, additional, Gasparini, Gaia, additional, Montella, Marco, additional, Contessi, Stefano, additional, Cocianni, Daniele, additional, Perotto, Maria, additional, Barone, Giuseppe, additional, Merlo, Marco, additional, Cappelletti, Alberto Maria, additional, Rosano, Giuseppe, additional, Sinagra, Gianfranco, additional, Pini, Daniela, additional, Savarese, Gianluigi, additional, and Metra, Marco, additional

Published
2023
Full Text
View/download PDF

15. Clinical burden and predictors of non-cardiovascular mortality and morbidity in advanced heart failure

Author

Stolfo, Davide, primary, Pagnesi, Matteo, additional, Chiarito, Mauro, additional, Baldetti, Luca, additional, Merlo, Marco, additional, Lombardi, Carlo Mario, additional, Loiacono, Ferdinando, additional, Cappelletti, Alberto Maria, additional, Contessi, Stefano, additional, Cocianni, Daniele, additional, Perotto, Maria, additional, Adamo, Marianna, additional, Calì, Filippo, additional, Inciardi, Riccardo Maria, additional, Tomasoni, Daniela, additional, Maccallini, Marta, additional, Villaschi, Alessandro, additional, Gasparini, Gaia, additional, Montella, Marco, additional, Barone, Giuseppe, additional, Pini, Daniela, additional, Metra, Marco, additional, and Sinagra, Gianfranco, additional

Published
2023
Full Text
View/download PDF

16. Role of ejection fraction in patients at risk for advanced heart failure: insights from the HELP‐HF registry

Author

Pagnesi, Matteo, primary, Lombardi, Carlo Mario, additional, Tedino, Chiara, additional, Chiarito, Mauro, additional, Stolfo, Davide, additional, Baldetti, Luca, additional, Adamo, Marianna, additional, Calì, Filippo, additional, Inciardi, Riccardo Maria, additional, Tomasoni, Daniela, additional, Loiacono, Ferdinando, additional, Maccallini, Marta, additional, Villaschi, Alessandro, additional, Gasparini, Gaia, additional, Montella, Marco, additional, Contessi, Stefano, additional, Cocianni, Daniele, additional, Perotto, Maria, additional, Barone, Giuseppe, additional, Merlo, Marco, additional, Cappelletti, Alberto Maria, additional, Sinagra, Gianfranco, additional, Pini, Daniela, additional, and Metra, Marco, additional

Published
2023
Full Text
View/download PDF

18. Guideline‐directed medical therapy in severe heart failure with reduced ejection fraction: An analysis from the HELP‐HF registry.

Author

Tomasoni, Daniela, Pagnesi, Matteo, Colombo, Giada, Chiarito, Mauro, Stolfo, Davide, Baldetti, Luca, Lombardi, Carlo Mario, Adamo, Marianna, Maggi, Giuseppe, Inciardi, Riccardo Maria, Loiacono, Ferdinando, Maccallini, Marta, Villaschi, Alessandro, Gasparini, Gaia, Montella, Marco, Contessi, Stefano, Cocianni, Daniele, Perotto, Maria, Barone, Giuseppe, and Merlo, Marco

Subjects
HEART failure, VENTRICULAR ejection fraction, ANGIOTENSIN receptors, ACE inhibitors, ANGIOTENSIN-receptor blockers, HEART failure patients
Abstract

Aim: Persistent symptoms despite guideline‐directed medical therapy (GDMT) and poor tolerance of GDMT are hallmarks of patients with advanced heart failure (HF) with reduced ejection fraction (HFrEF). However, real‐world data on GDMT use, dose, and prognostic implications are lacking. Methods and results: We included 699 consecutive patients with HFrEF and at least one 'I NEED HELP' marker for advanced HF enrolled in a multicentre registry. Beta‐blockers (BB) were administered to 574 (82%) patients, angiotensin‐converting enzyme inhibitors, angiotensin receptor blockers or angiotensin receptor–neprilysin inhibitors (ACEi/ARB/ARNI) were administered to 381 (55%) patients and 416 (60%) received mineralocorticoid receptor antagonists (MRA). Overall, ≥50% of target doses were reached in 41%, 22%, and 56% of the patients on BB, ACEi/ARB/ARNI and MRA, respectively. Hypotension, bradycardia, kidney dysfunction and hyperkalaemia were the main causes of underprescription and/or underdosing, but up to a half of the patients did not receive target doses for unknown causes (51%, 41%, and 55% for BB, ACEi/ARB/ARNI and MRA, respectively). The proportions of patients receiving BB and ACEi/ARB/ARNI were lower among those fulfilling the 2018 HFA‐ESC criteria for advanced HF. Treatment with BB and ACEi/ARB/ARNI were associated with a lower risk of death or HF hospitalizations (adjusted hazard ratio [HR] 0.63, 95% confidence interval [CI] 0.48–0.84, and HR 0.74, 95% CI 0.58–0.95, respectively). Conclusions: In a large, real‐world, contemporary cohort of patients with severe HFrEF, with at least one marker for advanced HF, prescription and uptitration of GDMT remained limited. A significant proportion of patients were undertreated due to unknown reasons suggesting a potential role of clinical inertia either by the prescribing healthcare professional or by the patient. Treatment with BB and ACEi/ARB/ARNI was associated with lower mortality/morbidity. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Role of ejection fraction in patients at risk for advanced heart failure: insights from the HELP‐HF registry.

Author

Pagnesi, Matteo, Lombardi, Carlo Mario, Tedino, Chiara, Chiarito, Mauro, Stolfo, Davide, Baldetti, Luca, Adamo, Marianna, Calì, Filippo, Inciardi, Riccardo Maria, Tomasoni, Daniela, Loiacono, Ferdinando, Maccallini, Marta, Villaschi, Alessandro, Gasparini, Gaia, Montella, Marco, Contessi, Stefano, Cocianni, Daniele, Perotto, Maria, Barone, Giuseppe, and Merlo, Marco

Subjects
VENTRICULAR ejection fraction, HEART failure, HEART failure patients, RENIN-angiotensin system, CARDIOVASCULAR disease related mortality
Abstract

Aims: Patients with heart failure (HF) with reduced ejection fraction (EF) (HFrEF), mildly reduced EF (HFmrEF), and preserved EF (HFpEF) may all progress to advanced HF, but the impact of EF in the advanced setting is not well established. Our aim was to assess the prognostic impact of EF in patients with at least one 'I NEED HELP' marker for advanced HF. Methods and results: Patients with HF and at least one high‐risk 'I NEED HELP' criterion from four centres were included in this analysis. Outcomes were assessed in patients with HFrEF (EF ≤ 40%), HFmrEF (EF 41–49%), and HFpEF (EF ≥ 50%) and with EF analysed as a continuous variable. The prognostic impact of medical therapy for HF in patients with EF < 50% and EF > 50% was also evaluated. All‐cause death was the primary endpoint, and cardiovascular death was a secondary endpoint. Among 1149 patients enrolled [mean age 75.1 ± 11.5 years, 67.3% males, 67.6% hospitalized, median follow‐up 260 days (inter‐quartile range 105–390 days)], HFrEF, HFmrEF, and HFpEF were observed in 699 (60.8%), 122 (10.6%), and 328 (28.6%) patients, and 1 year mortality was 28.3%, 26.2%, and 20.1, respectively (log‐rank P = 0.036). As compared with HFrEF patients, HFpEF patients had a lower risk of all‐cause death [adjusted hazard ratio (HRadj) 0.67, 95% confidence interval (CI) 0.48–0.94, P = 0.022], whereas no difference was noted for HFmrEF patients. After multivariable adjustment, a lower risk of all‐cause death (HRadj for 5% increase 0.94, 95% CI 0.89–0.99, P = 0.017) and cardiovascular death (HRadj for 5% increase 0.94, 95% CI 0.88–1.00, P = 0.049) was observed at higher EF values. Beta‐blockers and renin–angiotensin system inhibitors or sacubitril/valsartan were associated with lower mortality in both EF < 50% and EF ≥ 50% groups. Conclusions: Among patients with HF and at least one 'I NEED HELP' marker for advanced HF, left ventricular EF is still of prognostic value. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Atrial arrhythmias and heart failure: a “modern view” of an old paradox

Author

Rosario Pagliaro, Beniamino, primary, Mincione, Gianluca, additional, Taormina, Antonio, additional, Ceriotti, Carlo, additional, Poggio, Luca, additional, Cannata, Francesco, additional, Del Monaco, Guido, additional, Gitto, Mauro, additional, Battaglia, Vincenzo, additional, Pinna, Gabriele, additional, Galimberti, Paola, additional, Loiacono, Ferdinando, additional, Pellegrino, Marta, additional, Panico, Cristina, additional, Bragato, Renato, additional, Stefanini, Giulio, additional, Condorelli, Gianluigi, additional, Pini, Daniela, additional, and Frontera, Antonio, additional

Published
2023
Full Text
View/download PDF

23. Percutaneous Tricuspid Valve Repair

Author

Mangieri, Antonio, primary, Sticchi, Alessandro, primary, Gohar, Aisha, primary, Regazzoli, Damiano, primary, Fazzari, Fabio, primary, Pini, Daniela, primary, Pellegrino, Marta, primary, Pagliaro, Beniamino, primary, Loiacono, Ferdinando, primary, Chiarito, Mauro, primary, Reimers, Bernhard, primary, Praz, Fabien, primary, Latib, Azeem, primary, and Colombo, Antonio, primary

Published
2022
Full Text
View/download PDF

24. Atrial arrhythmias and heart failure: A "modern view" of an old paradox.

Author

Pagliaro, Beniamino Rosario, Mincione, Gianluca, Taormina, Antonio, Ceriotti, Carlo, Poggio, Luca, Cannata, Francesco, Del Monaco, Guido, Gitto, Mauro, Battaglia, Vincenzo, Pinna, Gabriele, Galimberti, Paola, Loiacono, Ferdinando, Pellegrino, Marta, Panico, Cristina, Bragato, Renato, Stefanini, Giulio, Condorelli, Gianluigi, Pini, Daniela, and Frontera, Antonio

Subjects
HEART failure treatment, HEART failure risk factors, ATRIAL arrhythmias, BIOMARKERS, MAGNETIC resonance imaging, RISK assessment, HEART failure, DISEASE complications
Abstract

Background: Heart failure (HF) and atrial arrhythmias (AAs) are two clinical conditions that characterize the daily clinical practice of cardiologists. In this perspective review, we analyze the shared etiopathogenetic pathways of atrial arrhythmias, which are the most common cause of atrial arrhythmias‐induced cardiomyopathy (AACM) and HF. Hypothesis: The aim is to explore the pathophysiology of these two conditions considering them as a "unicum", allowing the definition of a cardiovascular continuum where it is possible to predict the factors and to identify the patient phenotype most at risk to develop HF due to atrial arrhythmias. Methods: Potentially eligible articles, identified from the Electronic database (PubMed), and related references were used for a literature search that was conducted between January 2022 and January 2023. Search strategies were designed to identify articles that reported atrial arrhythmias in association with heart failure and vice versa. For the search we used the following keywords: atrial arrhythmias, atrial fibrillation, heart failure, arrhythmia‐induced cardiomyopathy, tachycardiomyopathy. We identified 620 articles through the electronic database search. Out of the 620 total articles we removed 320 duplicates, thus selecting 300 eligible articles. About 150 titles/abstracts were excluded for the following reasons: no original available data, no mention of atrial arrhythmias and heart failure crosstalk, very low quality analysis or evidence. We excluded also non‐English articles. When multiple articles were published on the same topic, the articles with the most complete set of data were considered. We preferentially included all papers that could provide the best evidence in the field. As a result, the present review article is based on a final number of 104 references. Results: While the pathophysiology of AACM and Heart Failure with reduced ejection fraction (HFrEF) has been studied in detail over the years, the causal link between atrial arrhythmias and heart failure with Preserved Ejection Fraction (HFpEF) has been often subject of interest. HFpEF is strictly related to AAs, which has always been considered significant risk factor. In this review we described the pathophysiological links between atrial fibrillation and heart failure. Furthermore, we illustrated and discussed the preclinical and clinical predicting factors of AF and HFpEF, and the corresponding targets of the available therapeutic agents. Finally, we outlined the patient phenotype at risk of developing AF and HFpEF (Central Illustration). Conclusions: In this review, we underline how these two clinical conditions (AF and HFpEF) represent a "unicum" and, therefore, should be considered as a single disease that can manifest itself in the same phenotype of patients but at different times. Furthermore, considering that today we have few therapeutic strategies to treat these patients, it would be good to make an early diagnosis in the initial stages of the disease or intervene even before the development of signs and symptoms of HF. This is possible only by paying greater attention to patients with predisposing factors and carrying out a targeted screening with the correct diagnostic methods. A systemic approach aimed at improving the immuno‐metabolic profile of these patients by lowering the body mass index, threatening the predisposing factors, lowering the mean heart rate and reducing the sympathetic nervous system activation is the key strategy to reduce the clinical impact of this disease. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

25. Prognostic impact of the updated 2018 HFA‐ESC definition of advanced heart failure: results from the HELP‐HF registry

Author

Pagnesi, Matteo, primary, Lombardi, Carlo Mario, additional, Chiarito, Mauro, additional, Stolfo, Davide, additional, Baldetti, Luca, additional, Loiacono, Ferdinando, additional, Tedino, Chiara, additional, Arrigoni, Luca, additional, Ghiraldin, Daniele, additional, Tomasoni, Daniela, additional, Inciardi, Riccardo Maria, additional, Maccallini, Marta, additional, Villaschi, Alessandro, additional, Gasparini, Gaia, additional, Montella, Marco, additional, Contessi, Stefano, additional, Cocianni, Daniele, additional, Perotto, Maria, additional, Barone, Giuseppe, additional, Merlo, Marco, additional, Cappelletti, Alberto Maria, additional, Sinagra, Gianfranco, additional, Pini, Daniela, additional, and Metra, Marco, additional

Published
2022
Full Text
View/download PDF

26. Prognostic value of tricuspid regurgitation

Author

Leone, Pier Pasquale, primary, Chiarito, Mauro, primary, Regazzoli, Damiano, primary, Pellegrino, Marta, primary, Monti, Lorenzo, primary, Pagliaro, Beniamino, primary, Loiacono, Ferdinando, primary, Stefanini, Giulio, primary, Pini, Daniela, primary, Reimers, Bernhard, primary, Colombo, Antonio, primary, Latib, Azeem, primary, and Mangieri, Antonio, primary

Published
2022
Full Text
View/download PDF

27. 491 Short-term prognostic implications of left ventricular myocardial work indices in advanced heart failure patients treated with repetitive Levosimendan infusions

Author

Fazzari, Fabio, primary, Cannata, Francesco, additional, Banfi, Daniele, additional, Pellegrino, Marta, additional, Pagliaro, Beniamino, additional, Loiacono, Ferdinando, additional, Mantovani, Riccardo, additional, Donghi, Valeria, additional, Curzi, Mirko, additional, Maurina, Matteo, additional, Condello, Francesco, additional, Liccardo, Gaetano, additional, Francone, Marco, additional, Condorelli, Gianluigi, additional, Stefanini, Giulio Giuseppe, additional, Pini, Daniela, additional, and Bragato, Renato Maria, additional

Published
2021
Full Text
View/download PDF

28. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Lescure, François-Xavier, primary, Honda, Hitoshi, additional, Fowler, Robert A, additional, Lazar, Jennifer Sloane, additional, Shi, Genming, additional, Wung, Peter, additional, Patel, Naimish, additional, Hagino, Owen, additional, Bazzalo, Ignacio J., additional, Casas, Marcelo M., additional, Nuñez, Sebastián A., additional, Pere, Yael, additional, Ibarrola, Carlos M., additional, Solis Aramayo, Marco A., additional, Cuesta, Maria C., additional, Duarte, Andrea E., additional, Gutierrez Fernandez, Pablo M., additional, Iannantuono, Maria A., additional, Miyazaki, Erica A., additional, Silvio, Javier P., additional, Scublinsky, Dario G., additional, Bales, Alessandra, additional, Catarino, Daniela, additional, Fiss, Elie, additional, Mohrbacher, Sara, additional, Sato, Victor, additional, Baylao, Antonio, additional, Cavalcante, Adilson, additional, Correa, Francini, additional, de Andrade, Celso A., additional, Furtado, Juvencio, additional, Ribeiro Filho, Nelson, additional, Telles, Valéria, additional, Trevelin, Leopoldo T., additional, Vipich, Ricardo, additional, Boldo, Rodrigo, additional, Borges, Paula, additional, Lobo, Suzana, additional, Luckemeyer, Graziela, additional, Machado, Luana, additional, Alves, Maysa B., additional, Iglessias, Ana C., additional, Lago, Marianna M., additional, Santos, Daniel W., additional, Chapdelaine, Hugo, additional, Falcone, Emilia L., additional, Jamal, Rahima, additional, Luong, Me-Linh, additional, Durand, Madeleine, additional, Doucet, Stephane, additional, Carrier, François-Martin, additional, Coburn, Bryan A., additional, Del Sorbo, Lorenzo, additional, Walmsley, Sharon L., additional, Belga, Sara, additional, Chen, Luke Y., additional, Mah, Allison D., additional, Steiner, Theodore, additional, Wright, Alissa J., additional, Hajek, J., additional, Adhikari, Neill, additional, Fowler, Robert A., additional, Daneman, Nick, additional, Khwaja, Kosar A., additional, Shahin, Jason, additional, Gonzalez, Carolina, additional, Silva, Rafael, additional, Lindh, Marcelo, additional, Maluenda, Gabriel, additional, Fernandez, Patricia, additional, Oyonarte, Maite, additional, Lasso, Martin, additional, Boyer, Alexandre, additional, Bronnimann, Didier, additional, Bui, Hoang-Nam, additional, Cazanave, Charles, additional, Chaussade, Helene, additional, Desclaux, Arnaud, additional, Ducours, Mailys, additional, Duvignaud, Alexandre, additional, Malvy, Denis, additional, Martin, Lisa, additional, Neau, Didier, additional, Nguyen, Duc, additional, Pistone, Thierry, additional, Soubrane-Wirth, Gaetane, additional, Leitao, Julie, additional, Allavena, Clotilde, additional, Biron, Charlotte, additional, Bouchez, Sabelline, additional, Gaborit, Benjamin, additional, Gregoire, Antoine, additional, Le Turnier, Paul, additional, Lecompte, Anne-Sophie, additional, Lecomte, Raphael, additional, Lefebvre, Maeva, additional, Raffi, Francois, additional, Boutoille, David, additional, Morineau, Pascale H., additional, Guéry, Romain, additional, Chatelus, Emmanuel, additional, Dumoussaud, Nathalie, additional, Felten, Renaud, additional, Luca, Florina, additional, Goichot, Bernard, additional, Schneider, Francis, additional, Taquet, Marie-Caroline, additional, Groh, Matthieu, additional, Roumier, Mathilde, additional, Neuville, Mathilde, additional, Bachelard, Antoine, additional, Isernia, Valentina, additional, Lescure, F-Xavier, additional, Phung, Bao-Chau, additional, Rachline, Anne, additional, Sautereau, Aurelie, additional, Vallois, Dorothee, additional, Bleher, Yves, additional, Boucher, Delphine, additional, Coudon, Clémentine, additional, Esnault, Jean, additional, Guimard, Thomas, additional, Leautez-Nainville, Sophie, additional, Merrien, Dominique, additional, Morrier, Marine, additional, Motte-Vincent, Pauline, additional, Gabeff, Romain, additional, Leclerc, Hélène, additional, Cozic, Céline, additional, Decours, Romain, additional, Février, Ronan, additional, Colin, Gwenhael, additional, Abgrall, Sophie, additional, Vignes, Dorothee, additional, Sterpu, Raluca, additional, Kuellmar, Mira, additional, Meersch-Dini, Melanie, additional, Weiss, Raphael, additional, Zarbock, Alexander, additional, Antony, Christiane, additional, Berger, Marc, additional, Brenner, Thorsten, additional, Taube, Christian, additional, Herbstreit, Frank, additional, Dolff, Sebastian, additional, Konik, Margarethe, additional, Schmidt, Karsten, additional, Zettler, Markus, additional, Witzke, Oliver, additional, Boell, Boris, additional, Garcia Borrega, Jorge, additional, Koehler, Philipp, additional, Zander, Thomas, additional, Dusse, Fabian, additional, Al-Sawaf, Othman, additional, Köhler, Philipp, additional, Eichenauer, Dennis, additional, Kochanek, Matthias, additional, Shimabukuro-Vornhagen, Alexander, additional, Mellinghoff, Sibylle, additional, Claßen, Annika, additional, Heger, Jan-Michel, additional, Meyer-Schwickerath, Charlotte, additional, Liedgens, Paul, additional, Heindel, Katrin, additional, Belkin, Ana, additional, Biber, Asaf, additional, Gilboa, Mayan, additional, Levy, Itzchak, additional, Litachevsky, Vladislav, additional, Rahav, Galia, additional, Finesod Wiedner, Anat, additional, Zilberman-Daniels, Tal, additional, Oster, Yonatan, additional, Strahilevitz, Jacob, additional, Sviri, Sigal, additional, Baldissera, Elena M., additional, Campochiaro, Corrado, additional, Cavalli, Giulio, additional, Dagna, Lorenzo, additional, De Luca, Giacomo, additional, Della Torre, Emanuel, additional, Tomelleri, Alessandro, additional, Bernasconi De Luca, Davide, additional, Capetti, Amedeo F., additional, Coen, Massimo, additional, Cossu, Maria V., additional, Galli, Massimo, additional, Giacomelli, Andrea, additional, Gubertini, Guido A., additional, Rusconi, Stefano, additional, Burastero, Giulia J., additional, Digaetano, Margherita, additional, Guaraldi, Giovanni, additional, Meschiari, Marianna, additional, Mussini, Cristina, additional, Puzzolante, Cinzia, additional, Volpi, Sara, additional, Aiello, Marina, additional, Ariani, Alarico, additional, Chetta, Alfredo A., additional, Frizzelli, Annalisa, additional, Ticinesi, Andrea, additional, Tuttolomondo, Domenico, additional, Aliberti, Stefano, additional, Blasi, Francesco B., additional, Di Pasquale, Marta F., additional, Misuraca, Sofia, additional, Pilocane, Tommaso, additional, Simonetta, Edoardo, additional, Aghelmo, Alessio M., additional, Angelini, Claudio, additional, Brunetta, Enrico, additional, Canonica, Giorgio W., additional, Ciccarelli, Michele, additional, Dal Farra, Sara, additional, De Santis, Maria, additional, Ferri, Sebastian, additional, Folci, Marco, additional, Guidelli, Giacomo M., additional, Heffler, Enrico M., additional, Loiacono, Ferdinando, additional, Malipiero, Giacomo, additional, Paoletti, Giovanni, additional, Pedale, Rosa, additional, Puggioni, Francesca A., additional, Racca, Francesca, additional, Zumbo, Aurora, additional, Satou, Morihiko, additional, Lisun, Tatyana, additional, Protsenko, Denis, additional, Rubtsov, Nikolay, additional, Beloglazova, Irina, additional, Fomina, Daria, additional, Lysenko, Mariana, additional, Serdotetskova, Sofia, additional, Firstov, Vitali, additional, Gordeev, Ivan, additional, Kokorin, Ilia, additional, Komissarova, Ksenia, additional, Lapochkina, Nina, additional, Luchinkina, Elena, additional, Malimon, Valentin, additional, Mamedguseyinova, Sevinch, additional, Polubatonova, Ksenia, additional, Suvorova, Natalia, additional, Arribas, Jose, additional, Borobia Perez, Alberto M., additional, de la Calle Prieto, Fernando, additional, Figueira, Juan Carlos, additional, Motejano Sanchez, Rocio, additional, Mora-Rillo, Marta, additional, Prados Sanchez, Concepcion, additional, Queiruga Parada, Javier, additional, Fernandez Arnalich, Francisco, additional, Guerro Barrientos, Maria, additional, Bendala Estrada, Alejandro, additional, Caballero Marcos, Aranzazu, additional, Garcia Leoni, Maria E., additional, García-Martínez, Rita, additional, Collado, Ana María, additional, Munoz Garcia, Patricia, additional, Torres do Rego, Ana, additional, Villalba García, María V., additional, Burrillo, Almudena, additional, Valerio Minero, Maricela, additional, Gijon Vidaurreta, Paloma, additional, Infante Herrero, Sonsoles, additional, Velilla, Elena, additional, Machado, Marina, additional, Olmedo, Maria, additional, Pinilla, Blanca, additional, Almirante Gragera, Benito, additional, Cañas Ruano, Maria de la Esperanza, additional, Contreras Medina, Sofia, additional, Cortés Herrera, Alejandro, additional, Falcó Ferrer, Vicenç, additional, Ferrer Roca, Ricard, additional, Nuvials Casals, Xavier, additional, Ribera Pascuet, Esteve, additional, Suanzes Diez, Paula, additional, Rebollo Castro, Pedro, additional, Garcia Alcaide, Felipe, additional, Soriano, Alejandro, additional, Oliver Caldes, Aina, additional, González Cordón, Ana, additional, Cardozo, Celia, additional, De la Mora Cañizo, Lorena, additional, Pena López, Romina, additional, Chamorro, Sandra, additional, Crespillo-Andujar, Clara, additional, Escudero Sanchez, Rosa, additional, Fortún-Abete, Jesús, additional, Monge-Maillo, Begoña, additional, Moreno Zamora, Ana, additional, Norman, Francesca, additional, Sanchez Conde, Matilde, additional, Serrano Villar, Sergio, additional, and Vizcarra, Pilar, additional

Published
2021
Full Text
View/download PDF

29. Lung ultrasound-guided therapy reduces acute decompensation events in chronic heart failure

Author

Marini, Claudia, primary, Fragasso, Gabriele, additional, Italia, Leonardo, additional, Sisakian, Hamayak, additional, Tufaro, Vincenzo, additional, Ingallina, Giacomo, additional, Stella, Stefano, additional, Ancona, Francesco, additional, Loiacono, Ferdinando, additional, Innelli, Pasquale, additional, Costantino, Marco Fabio, additional, Sahakyan, Laura, additional, Gabrielyan, Sirvard, additional, Avetisyan, Mariam, additional, Margonato, Alberto, additional, and Agricola, Eustachio, additional

Published
2020
Full Text
View/download PDF

30. The analysis of left atrial function predicts the severity of functional impairment in chronic heart failure : The FLASH multicenter study

Author

Cameli, Matteo, Sciaccaluga, Carlotta, Loiacono, Ferdinando, Simova, Iana, Miglioranza, Marcelo H., Nistor, Dan, Bandera, Francesco, Emdin, Michele, Giannoni, Alberto, Ciccone, Marco M., Devito, Fiorella, Guaricci, Andrea Igoren, Favale, Stefano, Lisi, Matteo, Mandoli, Giulia E., Henein, Michael, Mondillo, Sergio, Cameli, Matteo, Sciaccaluga, Carlotta, Loiacono, Ferdinando, Simova, Iana, Miglioranza, Marcelo H., Nistor, Dan, Bandera, Francesco, Emdin, Michele, Giannoni, Alberto, Ciccone, Marco M., Devito, Fiorella, Guaricci, Andrea Igoren, Favale, Stefano, Lisi, Matteo, Mandoli, Giulia E., Henein, Michael, and Mondillo, Sergio

Abstract

Background: Heart failure (HF) patients presentwith a variety of symptoms at different stages of the disease, but the underlying pathophysiology still is unclear. Left atrial (LA) function might be tightly related to changes in patients' symptoms, more than morphological and anatomic heart features, measurable by ultrasound imaging technique. This study sought to investigate the correlation between LA function, assessed by Speckle Tracking Echocardiography (STE) and Quality of Life (QoL), assessed by theMinnesota Livingwith Heart Failure Questionnaire (MLHFQ), in patients with chronic HF. Methods: Clinically stable HF outpatients (n = 369) were enrolled from 7 different international centres and underwent echocardiographic studies. Patients >75 years old and with atrial fibrillation were excluded. LA strain during reservoir phase (LASr) by STE was measured in all subjects by averaging the 6 atrial segments. LA size was assessed using biplane volume and 4-chamber area acquisition. Results: LASr strongly correlated with both MLHFQ total score (r = -0.87; p < 0.0001). Less significant correlations between MLHFQ and either LA volume or left ventricular global longitudinal strain (LV-GLS) were found (r = 0.28; p = 0.05 and r = 0.30; p = 0.01, respectively). No significant correlation was found between MLHFQ score, LVEF (r = -0.15; p = ns), E/E' ratio (r = 0.19; p = ns), and E/A ratio (r = 0.20; p = ns). Among all echocardiographic parameters analyzed, LASr presented the highest diagnostic accuracy (AUC = 0.74) in predicting a poor QoL (>45), when compared with LV-GLS (AUC = 0.61), LA volume (AUC = 0.54) and E/e' ratio (AUC = 0.51). Conclusions: In patients with HF, irrespective of etiology, LA function strongly correlates with patients' QoL. (C) 2019 Elsevier B.V. All rights reserved.

Published
2019
Full Text
View/download PDF

31. The analysis of left atrial function predicts the severity of functional impairment in chronic heart failure: The FLASH multicenter study

Author

Cameli, Matteo, primary, Sciaccaluga, Carlotta, additional, Loiacono, Ferdinando, additional, Simova, Iana, additional, Miglioranza, Marcelo H., additional, Nistor, Dan, additional, Bandera, Francesco, additional, Emdin, Michele, additional, Giannoni, Alberto, additional, Ciccone, Marco M., additional, Devito, Fiorella, additional, Guaricci, Andrea Igoren, additional, Favale, Stefano, additional, Lisi, Matteo, additional, Mandoli, Giulia E., additional, Henein, Michael, additional, and Mondillo, Sergio, additional

Published
2019
Full Text
View/download PDF

33. Oral direct thrombin inhibition: a double-edged sword?

Author

Fragasso, Gabriele, Corti, Angelo, Loiacono, Ferdinando, Margonato, Alberto, and D'Angelo, Armando

Subjects
side effects, myocardial infarction, Review-Article, new oral anticoagulants, oral direct thrombin inhibition, coronary artery disease
Abstract

New oral anticoagulants have been shown to be not inferior to vitamin K antagonists in reducing thrombo-embolic events in patients with non-valvular atrial fibrillation and venous thrombo-embolism. However, those among them whichdirectly inhibit thrombin have been associated with greater risk of myocardial infarction. In this article we review the pleiotropic physiological effects of thrombin and their potential link with the observed greater incidence of myocardial infarction during therapy with oral direct thrombin inhibitors. On this basis, we believe that further studies are necessary to clear out doubts on the use of these drugs in the general population and, more specifically, in patients with coronary artery disease. For these reasons, in our opinion at present it may be prudent to especially caution high risk patients initiating therapy with a direct thrombin inhibitor (or those who are already taking it) about this possible risk. For patients with established coronary artery disease an alternative oral anticoagulant may be at present a better choice.

Published
2015

38. Terapia metabolica per l'insufficienza cardiaca.

Author

Loiacono, Ferdinando, Alberti, Luca, Lauretta, Ludovica, Puccetti, Patrizia, Silipigni, Carmen, Margonato, Alberto, Fragasso, Gabriele, Loiacono, Ferdinando, Alberti, Luca, Lauretta, Ludovica, Puccetti, Patrizia, Silipigni, Carmen, Margonato, Alberto, and Fragasso, Gabriele

Abstract

Heart failure may promote metabolic changes such as insulin resistance, in part through neurohumoral activation, and determining an increased utilization of non-carbohydrate substrates for energy production. In fact, fasting blood ketone bodies as well as fat oxidation have been shown to be increased in patients with heart failure. The result is depletion of myocardial ATP, phosphocreatine and creatine kinase with decreased efficiency of mechanical work. A direct approach to manipulate cardiac energy metabolism consists in modifying substrate utilization by the failing heart. To date, the most effective metabolic treatments include several pharmacological agents that directly inhibit fatty acid oxidation. The results of current research are supporting the concept that shifting the energy substrate preference away from fatty acid metabolism and toward glucose metabolism could be an effective adjunctive treatment in patients with heart failure. Trimetazidine is the most studied drug in this context. Several small studies have evidenced the usefulness of such additional therapeutic tools for heart failure. More specifically, recent meta-analyses and a multicenter retrospective study have shown that additional use of trimetazidine in patients with heart failure, along with symptoms and cardiac function improvement, also provides a significant protective effect on all-cause mortality, cardiovascular events and hospitalization due to cardiac causes. Nevertheless, the exact role of metabolic therapy in heart failure is yet to be established, and a large multicenter randomized trial is necessary., info:eu-repo/semantics/published

Published
2014

39. Coinvolgimento cardiovascolare nella sindrome di Erdheim-Chester: aspetti clinici e terapeutici.

Author

Lauretta, Ludovica, Dagna, Lorenzo, Alberti, Luca, Loiacono, Ferdinando, De Cobelli, Francesco, Sanvito, Francesca, Moriggia, Stefano, Margonato, Alberto, Fragasso, Gabriele, Lauretta, Ludovica, Dagna, Lorenzo, Alberti, Luca, Loiacono, Ferdinando, De Cobelli, Francesco, Sanvito, Francesca, Moriggia, Stefano, Margonato, Alberto, and Fragasso, Gabriele

Abstract

Erdheim-Chester disease (ECD) is a rare form of non-Langerhans' cell histiocytosis of unknown etiology and its incidence is constantly increasing. ECD is characterized by a xantomatous or xanthogranulomatous infiltration of various tissues by foamy histiocytes surrounded by fibrosis. ECD is characterized by multi-organ involvement and is generally associated with a poor prognosis with a median survival of 32 months after diagnosis. Cardiovascular involvement concerns mainly the thoraco-abdominal aorta and pericardium. Less frequently, infiltration affects the myocardial tissue, especially the right atrium, and the valvular endocardium. Recently, the involvement of the vena cava has also been described. The diagnosis of ECD is made by the identification of foamy histiocytes CD68 positive and CD1a/S100 negative embedded in a polymorphic inflammatory tissue on biopsy. Despite the adoption of several therapeutic strategies until now prognosis has remained poor. Interferon-α can be considered the first line therapy, but its effects on central nervous system and cardiovascular localization have been shown to be often poor. In this context a combined treatment with the anti-TNFα monoclonal antibody infliximab and methotrexate seems to be effective and well tolerated., info:eu-repo/semantics/published

Published
2013

41. Structure and functional predictors of left atrial pressure inpatients with end-stage heart failure

Author

Cameli, Matteo, Loiacono, Ferdinando, Righini, Francesca M., Sparla, Stefania, Mandoli, Giulia E., Dokollari, Aleksander, Sassi, Carlo G., Bernazzali, Sonia, Maccherini, Massimo, Mondillo, Sergio, Henein, Michael, Cameli, Matteo, Loiacono, Ferdinando, Righini, Francesca M., Sparla, Stefania, Mandoli, Giulia E., Dokollari, Aleksander, Sassi, Carlo G., Bernazzali, Sonia, Maccherini, Massimo, Mondillo, Sergio, and Henein, Michael

42. Prognostic impact of the updated 2018 <scp>HFA‐ESC</scp> definition of advanced heart failure: results from the <scp>HELP‐HF</scp> registry

Author

Matteo Pagnesi, Carlo Mario Lombardi, Mauro Chiarito, Davide Stolfo, Luca Baldetti, Ferdinando Loiacono, Chiara Tedino, Luca Arrigoni, Daniele Ghiraldin, Daniela Tomasoni, Riccardo Maria Inciardi, Marta Maccallini, Alessandro Villaschi, Gaia Gasparini, Marco Montella, Stefano Contessi, Daniele Cocianni, Maria Perotto, Giuseppe Barone, Marco Merlo, Alberto Maria Cappelletti, Gianfranco Sinagra, Daniela Pini, Marco Metra, Pagnesi, Matteo, Lombardi, Carlo Mario, Chiarito, Mauro, Stolfo, Davide, Baldetti, Luca, Loiacono, Ferdinando, Tedino, Chiara, Arrigoni, Luca, Ghiraldin, Daniele, Tomasoni, Daniela, Inciardi, Riccardo Maria, Maccallini, Marta, Villaschi, Alessandro, Gasparini, Gaia, Montella, Marco, Contessi, Stefano, Cocianni, Daniele, Perotto, Maria, Barone, Giuseppe, Merlo, Marco, Cappelletti, Alberto Maria, Sinagra, Gianfranco, Pini, Daniela, and Metra, Marco

Subjects
Aged, 80 and over, Male, Advanced heart failure, Heart Failure Association, Cardiology, Stroke Volume, Heart failure, Middle Aged, Prognosis, Ventricular Function, Left, European Society Of Cardiology, Hospitalization, Mortality, Humans, Female, Registries, Cardiology and Cardiovascular Medicine, Aged
Abstract

Aims The Heart Failure Association of the European Society of Cardiology (HFA-ESC) proposed a definition of advanced heart failure (HF) that has not been validated, yet. We assessed its prognostic impact in a consecutive series of patients with high-risk HF. Methods and results The HELP-HF registry enrolled consecutive patients with HF and at least one high-risk 'I NEED HELP' marker, evaluated at four Italian centres between 1(st) January 2020 and 30(th) November 2021. Patients meeting the HFA-ESC advanced HF definition were compared to patients not meeting this definition. The primary endpoint was the composite of all-cause mortality or first HF hospitalization. Out of 4753 patients with HF screened, 1149 (24.3%) patients with at least one high-risk 'I NEED HELP' marker were included (mean age 75.1 +/- 11.5 years, 67.3% male, median left ventricular ejection fraction [LVEF] 35% [interquartile range 25%-50%]). Among them, 193 (16.8%) patients met the HFA-ESC advanced HF definition. As compared to others, these patients were younger, had lower LVEF, higher natriuretic peptides and a worse clinical profile. The 1-year rate of the primary endpoint was 69.3% in patients with advanced HF according to the HFA-ESC definition versus 41.8% in the others (hazard ratio [HR] 2.23, 95% confidence interval [CI] 1.82-2.74, p < 0.001). The prognostic impact of the HFA-ESC advanced HF definition was confirmed after multivariable adjustment for relevant covariates (adjusted HR 1.98, 95% CI 1.57-2.50, p < 0.001). Conclusions The HFA-ESC advanced HF definition had a strong prognostic impact in a contemporary, real-world, multicentre high-risk cohort of patients with HF.

Published
2022

43. Lung ultrasound-guided therapy reduces acute decompensation events in chronic heart failure

Author

Eustachio Agricola, Vincenzo Tufaro, Alberto Margonato, Sirvard Gabrielyan, Ferdinando Loiacono, Stefano Stella, Laura Sahakyan, Leonardo Italia, Hamayak Sisakian, Claudia Marini, Gabriele Fragasso, Mariam Avetisyan, Giacomo Ingallina, Marco Fabio Costantino, Francesco Ancona, Pasquale Innelli, Marini, Claudia, Fragasso, Gabriele, Italia, Leonardo, Sisakian, Hamayak, Tufaro, Vincenzo, Ingallina, Giacomo, Stella, Stefano, Ancona, Francesco, Loiacono, Ferdinando, Innelli, Pasquale, Costantino, Marco Fabio, Sahakyan, Laura, Gabrielyan, Sirvard, Avetisyan, Mariam, Margonato, Alberto, and Agricola, Eustachio

Subjects
Male, medicine.medical_specialty, Acute decompensated heart failure, heart failure, Physical examination, 030204 cardiovascular system & hematology, 03 medical and health sciences, 0302 clinical medicine, Predictive Value of Tests, Internal medicine, medicine, Clinical endpoint, Humans, Decompensation, heart failure with reduced ejection fraction, 030212 general & internal medicine, Lung, Ultrasonography, Interventional, Subclinical infection, Aged, Heart Failure, medicine.diagnostic_test, business.industry, medicine.disease, Heart failure, Relative risk, Therapy, Computer-Assisted, Acute Disease, Chronic Disease, Number needed to treat, Female, Cardiology and Cardiovascular Medicine, business, Follow-Up Studies
Abstract

ObjectivePulmonary congestion is the main cause of hospital admission in patients with heart failure (HF). Lung ultrasound (LUS) is a useful tool to identify subclinical pulmonary congestion. We evaluated the usefulness of LUS in addition to physical examination (PE) in the management of outpatients with HF.MethodsIn this randomised multicentre unblinded study, patients with chronic HF and optimised medical therapy were randomised in two groups: ‘PE+LUS’ group undergoing PE and LUS and ‘PE only’ group. Diuretic therapy was modified according to LUS findings and PE, respectively. The primary endpoint was the reduction in hospitalisation rate for acute decompensated heart failure (ADHF) at 90-day follow-up. Secondary endpoints were reduction in NT-proBNP, quality-of-life test (QLT) and cardiac mortality at 90-day follow-up.ResultsA total of 244 patients with chronic HF and optimised medical therapy were enrolled and randomised in ‘PE+LUS’ group undergoing PE and LUS, and in ‘PE only’ group. Thirty-seven primary outcome events occurred. The hospitalisation for ADHF at 90 day was significantly reduced in ‘PE+LUS’ group (9.4% vs 21.4% in ‘PE only’ group; relative risk=0.44; 95% CI 0.23 to 0.84; p=0.01), with a reduction of risk for hospitalisation for ADHF by 56% (p=0.01) and a number needed to treat of 8.4 patients (95% CI 4.8 to 34.3). At day 90, NT-proBNP and QLT score were significantly reduced in ‘PE+LUS’ group, whereas in ‘PE only’ group both were increased. There were no differences in mortality between the two groups.ConclusionsLUS-guided management reduces hospitalisation for ADHF at mid-term follow-up in outpatients with chronic HF.

Published
2020

44. New pharmacological targets in the treatment of heart failure: Inhibition of free fatty oxidation by trimetazidine

Author

Signoretta, N., Luca Paolo Alberti, Lauretta, L., Demarchi, B., Loiacono, F., Margonato, A., Fragasso, G., Signoretta, Noelia, Alberti, Luca, Lauretta, Ludovica, Demarchi, Barbara, Loiacono, Ferdinando, Margonato, Alberto, and Fragasso, Gabriele

Subjects
Endocrinology, Diabetes and Metabolism, Left ventricular function, Trimetazidine, Free fatty acid inhibitor, Heart failure, Carnitine palmitoyl transferase I, Metabolic therapy, Cardiology and Cardiovascular Medicine, Myocardial metabolism
Abstract

Heart failure may promote alterations of cardiac metabolism, resulting in the depletion of myocardial ATP, phosphocreatine and creatine kinase with decreased efficiency of mechanical work. A direct approach to manipulate cardiac energy metabolism consists in modifying substrate utilization by the failing heart. To date, the most effective metabolic treatments include pharmacological agents that directly inhibit fatty acid oxidation. Trimetazidine (Vastarel® MR) appears to be the most investigated agent in this setting. The results of current research support the concept that shifting the energy substrate preference away from fatty acid metabolism and towards glucose metabolism could be an effective adjunctive treatment in patients with heart failure. More specifically, very recent meta-analyses have confirmed that the additional use of trimetazidine in heart failure patients may yield a significant protective effect for all-cause mortality, cardiovascular events and hospitalization for cardiac causes, improve clinical symptoms and cardiac function, and simultaneously ameliorate left ventricular remodeling. Certainly, in order to clarify the exact therapeutic role of metabolic therapy in heart failure, a large multicenter randomized controlled trial should be performed.

Published
2012

45. Left ventricular fibrosis as a main determinant of filling pressures and left atrial function in advanced heart failure.

Author

Mandoli GE, Cameli M, Pastore MC, Loiacono F, Righini FM, D'Ascenzi F, Focardi M, Cavigli L, Lisi M, Bisleri G, Dokollari A, Bernazzali S, Maccherini M, Valente S, and Henein MY

Subjects
Humans, Female, Middle Aged, Aged, Male, Atrial Function, Left, Ventricular Function, Left, Heart Ventricles, Stroke Volume, Fibrosis, Heart Failure, Ventricular Dysfunction, Left
Abstract

Aims: Advanced heart failure (AdHF) is characterized by variable degrees of left ventricular (LV) dysfunction, myocardial fibrosis, and raised filling pressures which lead to left atrial (LA) dilatation and cavity dysfunction. This study investigated the relationship between LA peak atrial longitudinal strain (PALS), assessed by speckle-tracking echocardiography (STE), and invasive measures of LV filling pressures and fibrosis in a group of AdHF patients undergoing heart transplantation (HTX)., Methods and Results: We consecutively enrolled patients with AdHF who underwent HTX at our Department. Demographic and basic echocardiographic data were registered, then invasive intracardiac pressures were obtained from right heart catheterization, and STE was also performed. After HTX, biopsy specimens from explanted hearts were collected to quantify the degree of LV myocardial fibrosis. Sixty-four patients were included in the study (mean age 62.5 ± 11 years, 42% female). The mean LV ejection fraction (LVEF) was 26.7 ± 6.1%, global PALS was 9.65 ± 4.5%, and mean pulmonary capillary wedge pressure (PCWP) was 18.8 ± 4.8 mmHg. Seventy-three % of patients proved to have severe LV fibrosis. Global PALS was inversely correlated with PCWP (R = -0.83; P < 0.0001) and with LV fibrosis severity (R = -0.78; P < 0.0001) but did not correlate with LVEF (R = 0.15; P = 0.2). Among echocardiographic indices of LV filling pressures, global PALS proved the strongest [area under the curve 0.955 (95% confidence interval 0.87-0.99)] predictor of raised (>18 mmHg) PCWP., Conclusion: In patients with AdHF, reduced global PALS strongly correlated with the invasively assessed LV filling pressure and degree of LV fibrosis. Such relationship could be used as non-invasive indicator for optimum patient stratification for therapeutic strategies., Competing Interests: Conflict of interest: None declared., (© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)

Published
2024
Full Text
View/download PDF

46. [Metabolic therapy for heart failure].

Author

Loiacono F, Alberti L, Lauretta L, Puccetti P, Silipigni C, Margonato A, and Fragasso G

Subjects
Carbohydrate Metabolism drug effects, Evidence-Based Medicine, Humans, Insulin Resistance, Myocardium metabolism, Treatment Outcome, Trimetazidine pharmacology, Vasodilator Agents pharmacology, Fatty Acids metabolism, Glucose metabolism, Heart Failure drug therapy, Heart Failure metabolism, Trimetazidine therapeutic use, Vasodilator Agents therapeutic use
Abstract

Heart failure may promote metabolic changes such as insulin resistance, in part through neurohumoral activation, and determining an increased utilization of non-carbohydrate substrates for energy production. In fact, fasting blood ketone bodies as well as fat oxidation have been shown to be increased in patients with heart failure. The result is depletion of myocardial ATP, phosphocreatine and creatine kinase with decreased efficiency of mechanical work. A direct approach to manipulate cardiac energy metabolism consists in modifying substrate utilization by the failing heart. To date, the most effective metabolic treatments include several pharmacological agents that directly inhibit fatty acid oxidation. The results of current research are supporting the concept that shifting the energy substrate preference away from fatty acid metabolism and toward glucose metabolism could be an effective adjunctive treatment in patients with heart failure. Trimetazidine is the most studied drug in this context. Several small studies have evidenced the usefulness of such additional therapeutic tools for heart failure. More specifically, recent meta-analyses and a multicenter retrospective study have shown that additional use of trimetazidine in patients with heart failure, along with symptoms and cardiac function improvement, also provides a significant protective effect on all-cause mortality, cardiovascular events and hospitalization due to cardiac causes. Nevertheless, the exact role of metabolic therapy in heart failure is yet to be established, and a large multicenter randomized trial is necessary.

Published
2014
Full Text
View/download PDF

47. [Cardiovascular involvement in Erdheim-Chester syndrome: clinical and therapeutic implications].

Author

Lauretta L, Dagna L, Alberti L, Loiacono F, De Cobelli F, Sanvito F, Moriggia S, Margonato A, and Fragasso G

Subjects
Cardiovascular Diseases therapy, Erdheim-Chester Disease drug therapy, Erdheim-Chester Disease etiology, Humans, Cardiovascular Diseases etiology, Erdheim-Chester Disease complications
Abstract

Erdheim-Chester disease (ECD) is a rare form of non-Langerhans' cell histiocytosis of unknown etiology and its incidence is constantly increasing. ECD is characterized by a xantomatous or xanthogranulomatous infiltration of various tissues by foamy histiocytes surrounded by fibrosis. ECD is characterized by multi-organ involvement and is generally associated with a poor prognosis with a median survival of 32 months after diagnosis. Cardiovascular involvement concerns mainly the thoraco-abdominal aorta and pericardium. Less frequently, infiltration affects the myocardial tissue, especially the right atrium, and the valvular endocardium. Recently, the involvement of the vena cava has also been described. The diagnosis of ECD is made by the identification of foamy histiocytes CD68 positive and CD1a/S100 negative embedded in a polymorphic inflammatory tissue on biopsy. Despite the adoption of several therapeutic strategies until now prognosis has remained poor. Interferon-α can be considered the first line therapy, but its effects on central nervous system and cardiovascular localization have been shown to be often poor. In this context a combined treatment with the anti-TNFα monoclonal antibody infliximab and methotrexate seems to be effective and well tolerated.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results